降压治疗对原发性高血压患者脑钠素影响的实验研究

医学研究与教育 ›› 2012, Vol. 29 ›› Issue (5): 23-27.

降压治疗对原发性高血压患者脑钠素影响的实验研究

牟丽娜¹,郝玉明²

1.哈励逊国际和平医院心内科,河北衡水 053000
2.河北医科大学附属第二医院心内科,河北石家庄 050000

收稿日期:2016-10-09 修回日期:2016-10-09 出版日期:2012-10-25 发布日期:2012-10-25

Received:2016-10-09 Revised:2016-10-09 Online:2012-10-25 Published:2012-10-25

摘要/Abstract

摘要： 目的观测苯那普利、缬沙坦、缬沙坦+小剂量利尿剂在降压治疗的同时对血浆脑钠素(BNP)水平的影响.方法将117例原发性高血压(EH)患者随机分为三组,缬沙坦80 mg组,苯那普利10 mg组和缬沙坦80 mg+双氢克尿噻(双克)12.5 mg组,共治疗4周,比较三组药物降压前后血浆BNP水平的变化,并对比三组治疗的异同.结果(1)与单用苯那普利和缬沙坦相比,缬沙坦+小剂量双克组对收缩压的影响差异无统计学意义(P>0.05),而降低舒张压的效果较显著(P<0.05).(2)治疗前后各组自身的脑钠素水平变化差异均有统计学意义(P<0.05).组间比较:缬沙坦+双克组较其他两组脑钠素水平变化明显(均P<0.05),而苯那普利组与缬沙坦组之间比较差异无统计学意义(P>0.05).结论(1)苯那普利和缬沙坦两种药物具有很好的降压疗效,同时能显著降低EH患者的血浆BNP水平,但对BNP的影响二者之间差异无统计学意义.(2)与单用苯那普利或缬沙坦相比,缬沙坦+小量利尿剂降低舒张压效果较显著,同时对BNP的影响也较大.

关键词: 原发性高血压, 脑钠素, 缬沙坦, 苯那普利, 双氢克尿噻

中图分类号:

牟丽娜,郝玉明. 降压治疗对原发性高血压患者脑钠素影响的实验研究[J]. 医学研究与教育, 2012, 29(5): 23-27.

参考文献

[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会, Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 中国心血管病预防指南 [J]. 中华心血管病杂志 2011.doi:10.3760/cma.j.issn.0253-3758.2011.01.002
[2] 王敬民, 金炜, 吴潇. 缬沙坦治疗原发性高血压对内源性纤溶活性的影响 [J]. 临床心血管病杂志 2002.doi:10.3969/j.issn.1001-1439.2002.05.008
[3] YOSHIMOTO T. Vascular action of circulating and local natriuretic peptide systems is potentiated in obese/hyperglycemic and hypertensive rats [J]. Endocrinology 1996, 13(12).
[4] 《中国高血压防治指南修订》委员会. 中国高血压防治指南(2005年修订版) [M]. 北京:人民卫生出版社 2006.
[5] DANCHIN N, CUCHERAT M, THUIUEZ C. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction:an overview of long-term randomized controlled trails [J]. Archives of Internal Medicine 2006, 166(06).
[6] PAHOR M, PSATY B M, ALDERMAN M H. Therapeutic benefits of ACE inhibitors and other atinhypertensive drugs in patients with type 2 diabetes [J]. Diabetes Care 2000, 23(03).
[7] McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. [J]. The New England journal of medicine 2010, 16(16).
[8] Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de-Cotret PR, Chen R, Palmer A. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. [J]. Clinical therapeutics 2007, 7(7).
[9] MARIA S, JARKKO K, ILKKA P. NG-nitro-L-arginine methy1 ester-induced hypertension and natriuretic peptide gene expression:inhibition by angiotensin II type 1 receptor antagonism [J]. Journal of Cardiovascular Pharmacology 2002, 40(03).
[10] Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 trials. [J]. The American Journal of Medicine 2009, 3(3).
[11] ESC Committee for Practice Guideline(CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure:the Task Force on Acute Heart Failure of the European Society of Cardiology [J]. European Heart Journal 2005, 26(04).